Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.34 |
| ▸ | ABL1 | P00519 | 6/20 | 0.32 |
| ▸ | BCR | P11274 | 6/20 | 0.32 |
| ▸ | EPHA4 | P54764 | 2/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 2/20 | 0.31 |
| ▸ | FLT3 | P36888 | 2/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13360788 | 0.83 | EPHA4 (0.48) | KDRABL1BCREPHA4JAK2 | |
| SCHEMBL13360769 | 0.83 | HTR7 (0.38) | KDRABL1EPHA4CSNK1A1TYRO3 | |
| SCHEMBL13360793 | 0.82 | HRH3 (0.37) | KDRABL1EPHA4CSNK1A1DYRK1B | |
| SCHEMBL13360842 | 0.80 | EGFR (0.37) | EPHA4 | |
| SCHEMBL13360783 | 0.77 | EPHA4 (0.34) | KDRABL1EPHA4CSNK1A1TYRO3 | |
| SCHEMBL13360819 | 0.76 | PIK3CD (0.37) | KDRABL1CSNK1A1TYRO3DYRK1B | |
| SCHEMBL13360811 | 0.76 | EPHA4 (0.36) | EPHA4 | |
| SCHEMBL13360843 | 0.75 | BTK (0.42) | KDRABL1FLT3SRCGSK3B | |
| SCHEMBL13360787 | 0.74 | EPHA4 (0.53) | KDRABL1EPHA4CSNK1A1TYRO3 | |
| SCHEMBL13360799 | 0.73 | ABL1 (0.38) | KDRABL1BCREPHA4CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | KDR 41/4885ABL1 20/4885BCR 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.